BioLineRx Ltd. Sponsored ADR
BLRX
BioLineRx Ltd. Sponsored ADR is a biopharmaceutical company focused on developing and commercializing therapies for oncology and other serious diseases. BioLineRx Ltd. pursues a portfolio centered on cancer treatment, including clinical-stage and marketed assets that address areas such as stem cell mobilization, solid tumors, and rare disease-related needs. The company works through research, development, and partnership-based programs that advance small-molecule and peptide-based candidates across clinical stages. Its current activity also includes therapies designed for immuno-oncology, DNA damage response, and supportive care applications, along with legacy products in dermatology. BioLineRx Ltd. plays a niche role in the healthcare market by concentrating on specialized therapeutic candidates that target unmet medical needs and by collaborating with external partners to support development and commercialization efforts.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1M
▼ -95.9% YoY
Net Income (TTM)
-$10M
▲ +78.0% YoY
Op. Margin
-874.28%
▼ -805.6pp YoY
ROIC
-26.22%
▲ +30.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$11M
▲ +81.6% YoY
Op. Cash Flow (TTM)
-$11M
▲ +62.0% YoY
Net Debt
-$11M
Net Cash Position
Cash & Equiv.
$21M
Continue Research
Peers
Biotechnology · Pick stocks to compare with BLRX
BioLineRx Ltd. Sponsored ADR (BLRX) in four numbers
- Quality score
- 20/100
- Best check: share count change, -92.0%. Weakest: return on capital, -26.2%.
- Quality
Questions about BioLineRx Ltd. Sponsored ADR
Is BioLineRx Ltd. Sponsored ADR (BLRX) overvalued?
At $1.12, BioLineRx Ltd. Sponsored ADR's price is 78% below the $5.06 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is BioLineRx Ltd. Sponsored ADR's fair value?
Intrinsiqq's calculator puts BioLineRx Ltd. Sponsored ADR's fair value at $5.06 a share. It grows revenue per share 30% a year for 5 years, applies an exit P/S of 7, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $3.79. Every input can be changed on the Intrinsic Value tab.
Is BioLineRx Ltd. Sponsored ADR a high-quality business?
BioLineRx Ltd. Sponsored ADR scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is share count change at -92.0%, and its weakest is return on capital at -26.2%. The Quality tab shows every check against its target.
Does BioLineRx Ltd. Sponsored ADR (BLRX) pay a dividend?
No. BioLineRx Ltd. Sponsored ADR (BLRX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 17 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BLRX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.